Condition: Multiple Myeloma · Sponsor: Christopher Strouse
This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.
This description comes directly from the study's public registry record.
Christopher Strouse, MD · (319) 356-0489 · christopher-strouse@uiowa.edu
Always discuss trial participation with your own doctor first.
| University of Iowa Health Care | Iowa City, Iowa, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07581704